

How basic research findings were expanded into a patient-focused intervention

Connie J Kim, PhD Candidate (with Dr. Rupert Kaul)

Session: Challenge Panel, Where does basic science fit in impact-focused research?

November 19, 2013 – 15:00-16:15




OHTN 2013
RESEARCH
CONFERENCE

NOVEMBER 17-19, 2013

CHANGING THE COURSE OF THE
HIV PREVENTION, ENGAGEMENT AND
TREATMENT CASCADE

OHTN funded translational basic science

1. Sheth et al, Mucosal Imm 2008
2. Chege et al, AIDS, 2011
3. Kim et al, Mucosal Imm 2012
4. Kim et al, J Immunol 2013



OHTN funding: impact-focused clinical trial

- Probiotics: live bacteria that may confer health benefits to the host
 - AKA “good bacteria”
- VSL#3 is a high potency probiotic blend of 8 different bacteria
- 450 billion live bacteria per sachet
- Previous studies show improved gut function in inflammatory gut disease and SIV



Question: Can probiotics accelerate gut restoration and reduce immune activation in HIV-infected individuals?

PROOV IT I : HIV-infected people starting HIV meds (6 months)

PROOV IT II : Immune “non-responders” already on HIV meds (12 months)

Acknowledgements

This study is supported by the CTN, OHTN and VSL Pharmaceuticals Inc.

- **Supervisor:** Dr. Rupert Kaul
- **Previous students:** Dr. Prameet Sheth and Dr. Duncan Chege
- **Co-investigators:** Dr. Mario Ostrowski, Dr. Colin Kovacs, Dr. Gabor Kandel, Dr. Sharon Walmsley, Robert Reinhard and Ron Rosenes
- **Community Scholars:** Robert Reinhard and Ron Rosenes
- **Collaborators:** Dr. Jon Meddings and Dr. Kenneth Croitoru

